NHWK - NightHawk Biosciences, Inc. Stock Price, Fair Value and News

0.16USD Market Closed

Market Summary

USD0.16

Market Closed

NHWK Stock Price

View Fullscreen

NHWK RSI Chart

NHWK Valuation

Market Cap

5.8M

Price/Earnings (Trailing)

-0.13

Price/Sales (Trailing)

0.82

EV/EBITDA

-0.15

Price/Free Cashflow

-0.17

NHWK Price/Sales (Trailing)

NHWK Profitability

EBT Margin

-625.28%

Return on Equity

-144.02%

Return on Assets

-88.6%

Free Cashflow Yield

-581.4%

NHWK Fundamentals

NHWK Revenue

Revenue (TTM)

7.0M

Rev. Growth (Yr)

7.5K%

Rev. Growth (Qtr)

570.43%

NHWK Earnings

Earnings (TTM)

-45.2M

Earnings Growth (Yr)

64.48%

Earnings Growth (Qtr)

58.82%

Breaking Down NHWK Revenue

Last 30 days

-48.4%

Last 90 days

-64.4%

How does NHWK drawdown profile look like?

NHWK Financial Health

Current Ratio

0.47

NHWK Investor Care

Shares Dilution (1Y)

38.32%

Diluted EPS (TTM)

-1.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	939.7K	1.5M	2.2M	7.0M
2022	1.8M	1.4M	935.4K	386.2K
2021	2.6M	2.5M	2.1M	2.1M
2020	3.2M	3.5M	4.3M	2.9M
2019	5.7M	4.9M	3.1M	3.0M
2018	2.6M	3.7M	4.7M	5.8M
2017	538.0K	734.4K	1.1M	1.3M
2016	43.3K	142.7K	242.2K	341.6K
2015	38.7K	0	0	0
2014	17.7K	25.3K	32.9K	40.6K
2013	0	0	0	10.1K
2012	0	0	0	3.1K

Get all data in R, Python etc through our Historical Stock Data APIs

Which funds bought or sold NHWK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-13,422	-	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-28,660	16,683	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-7,552	4,395	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-143	-	-%
May 15, 2024	PACIFIC CAPITAL WEALTH ADVISORS, INC	unchanged	-	-4.00	2.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	6.97	-1,777	1,153	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	reduced	-38.29	-11,182	3,284	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-27,830	16,200	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-12.41	-4,830	2,296	-%

Are Funds Buying or Selling NHWK?

Are funds buying NHWK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NHWK

No. of Funds

Unveiling NightHawk Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 14, 2024	wolf jeffrey alan	10.5%	4,126,178	SC 13D/A
Dec 12, 2023	wolf jeffrey alan	13.5%	3,883,997	SC 13D/A

Recent SEC filings of NightHawk Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 16, 2024	424B4	Prospectus Filed
May 16, 2024	424B4	Prospectus Filed
May 16, 2024	8-K	Current Report
May 16, 2024	NT 10-Q	NT 10-Q
May 14, 2024	SC 13D/A	13D - Major Acquisition
May 13, 2024	EFFECT	EFFECT
May 13, 2024	8-K	Current Report
May 13, 2024	S-1/A	Initial Public Offering
May 13, 2024	S-1MEF	S-1MEF

Peers (Alternatives to NightHawk Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

NightHawk Biosciences, Inc. News

Latest updates

NightHawk Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	570.4%	4,848,034	723,126	657,778	765,900	63,917	58,861	50,981	212,418	613,100	501,567	459,494	538,645	603,192	849,732	593,165	901,880	1,999,116	6,439	342,487	701,062	2,058,136
Costs and Expenses	-16.2%	9,876,199	11,782,921	14,973,599	13,801,388	13,171,099	10,599,434	9,764,061	7,688,970	-	8,066,635	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	9,764,061	7,688,970	14,110,758	8,066,635	7,174,559	8,179,893	7,629,950	9,980,856	5,435,471	6,026,054	5,402,679	6,361,492	5,396,600	6,634,138	7,604,636
S&GA Expenses	2.3%	6,220,541	6,082,539	7,393,197	6,820,550	6,728,141	4,838,169	4,890,544	3,776,623	5,817,226	3,390,093	2,853,265	4,767,645	3,283,021	6,579,193	1,801,674	3,270,548	2,229,819	1,993,136	1,860,459	3,347,601	2,298,107
R&D Expenses	-44.2%	2,877,614	5,155,359	5,732,961	6,995,848	6,536,663	5,379,780	4,726,517	3,933,347	4,451,194	4,381,542	4,216,294	3,406,248	4,192,929	3,172,663	2,790,797	2,782,506	3,287,860	3,129,356	3,424,141	3,172,247	5,476,529
EBITDA Margin	73.8%	-5.33	-20.35	-29.46	-45.33	-101	-44.03	-27.94	-19.51	-16.28	-12.98	-11.73	-10.34	-8.65	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-191,000	-	-	-	42,697	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-571,120	-	-	37,063	-3,326,000	-	-	-	-	-	-	-	-	-	-	-	-	45,178	-320,253
Earnings Before Taxes	54.5%	-5,103,200	-11,206,263	-14,532,822	-12,895,136	-13,142,953	-10,609,762	-10,263,910	-8,189,798	-13,754,840	-7,548,225	-6,620,576	-7,623,140	-6,554,718	-8,916,433	-4,536,818	-6,373,420	-3,289,817	-6,330,913	-4,944,905	-5,773,903	-5,447,774
EBT Margin	73.3%	-6.25	-23.42	-33.10	-49.92	-109	-45.78	-28.85	-20.21	-16.82	-13.48	-12.12	-10.69	-8.95	-	-	-	-	-	-	-	-
Net Income	58.8%	-5,408,035	-13,132,470	-13,892,016	-12,784,647	-15,224,483	-13,258,350	-6,831,286	-8,120,587	-13,563,373	-7,432,720	-6,543,197	-7,532,178	-6,451,592	-8,851,609	-4,454,430	-6,292,106	-3,336,624	-6,194,598	-4,770,870	-5,715,476	-4,938,300
Net Income Margin	74.0%	-6.46	-24.89	-35.67	-51.19	-112	-44.66	-26.09	-19.96	-16.60	-13.30	-11.99	-10.56	-8.84	-	-	-	-	-	-	-	-
Free Cashflow	86.9%	-1,210,563	-9,267,625	-7,620,202	-15,419,762	-8,689,252	-12,349,824	6,526,130	-11,305,416	-11,911,103	-13,472,956	-9,436,176	-5,213,384	-6,459,424	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-27.0%	51,038	69,915	80,184	91,518	104,397	119,912	131,855	114,267	120,961	132,655	138,790	144,470	124,195	129,710	58,153	37,821	25,957	24,452	29,703	33,898	37,764
Current Assets	-80.3%	4,761	24,180	22,782	34,358	50,054	66,474	79,389	86,578	99,331	111,831	124,759	133,878	113,794	119,142	47,601	27,127	15,209	15,790	20,238	24,406	28,714
Cash Equivalents	-90.9%	185	2,043	5,837	7,827	3,192	13,658	10,243	14,585	8,054	7,882	21,567	31,157	10,932	24,808	20,668	20,739	9,040	9,334	13,828	17,897	22,154
Inventory	-	909	-	-	-	-	-	5,844	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-5.9%	17,587	18,684	19,111	19,431	20,439	20,731	5,253	3,099	2,158	1,767	4,146	968	676	720	669	706	559	610	567	621	643
Goodwill	-	-	-	3,873	3,302	3,302	3,215	5,068	-	-	1,452	1,452	1,452	1,452	1,452	1,452	1,452	1,452	1,452	2,189	2,189	2,189
Liabilities	-37.6%	22,743	36,469	33,117	31,179	31,960	33,713	33,141	9,568	8,928	8,790	8,317	8,010	8,701	8,812	11,017	11,290	12,799	8,278	7,747	7,422	7,521
Current Liabilities	-58.8%	10,100	24,488	15,341	17,479	18,037	14,451	15,132	5,315	4,721	3,290	3,352	3,046	3,657	3,802	6,218	6,937	8,435	4,794	4,500	4,283	4,872
Shareholder's Equity	-13.5%	31,397	36,293	47,067	60,339	73,923	87,539	99,964	104,698	112,034	123,865	130,472	136,460	115,494	120,898	47,136	26,531	13,158	16,173	21,955	26,476	30,243
Retained Earnings	-2.2%	-254,400	-249,000	-235,800	-221,938	-209,153	193,929	180,671	-173,800	-165,718	-152,200	-144,700	-138,200	-130,647	-124,195	-115,300	-110,889	-104,597	-101,261	-95,066	-90,295	-84,580
Additional Paid-In Capital	0.2%	285,713	285,090	284,454	283,785	283,019	281,320	280,603	279,800	278,890	277,098	276,225	275,619	247,048	245,741	163,008	137,693	118,180	117,836	117,351	116,943	114,883
Shares Outstanding	0.5%	26,219	26,082	26,047	26,049	25,661	25,613	25,598	25,594	25,650	25,138	25,137	24,200	22,832	-	-	-	-	-	-	-	-
Minority Interest	-9.0%	-3,102	-2,845	-1,666	-1,596	-1,486	-1,340	-1,250	-1,143	-1,074	-1,029	-913	-836	-745	-642	-577	-495	-413	-460	-324	-150	-46.60
Float	-	-	-	16,554	-	-	-	65,407	-	-	-	169,017	-	-	-	89,997	-	-	-	23,393	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	87.2%	-1,077	-8,451	-8,208	-13,794	-7,842	3,571	8,786	-10,214	-11,389	-15,736	-6,152	-4,849	-6,442	-5,503	-4,294	-5,780	-252	-4,347	-4,061	-4,175	-5,998
Share Based Compensation	-12.0%	528	600	700	800	1,681	700	800	910	1,782	900	600	2,898	353	4,700	400	900	324	500	400	2,060	166
Cashflow From Investing	-73.1%	2,099	7,815	8,836	13,486	7,369	-148	-13,027	16,798	11,622	2,121	-3,405	-567	-8,361	-66,311	-20,691	-54.85	-42.85	-132	-37.07	-81.38	-5,616
Cashflow From Financing	-3866.9%	-6,201	165	-2,617	-298	-4,761	-34.53	-55.95	-55.19	-61.51	-61.16	-30.17	25,643	923	75,954	24,900	17,551	-1.97	-1*	-	-	12,771

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NHWK Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Revenue	$ 6,994,838	$ 370,176
Operating expenses:
Cost of revenues	2,736,998	81,295
Research and development	20,119,791	20,223,495
Selling, general and administrative	26,170,221	20,130,546
In-process research and development impairment		3,500,000
Change in fair value of contingent consideration		(3,342,515)
Total operating expenses	49,027,010	40,592,821
Operating loss	(42,032,172)	(40,222,645)
Change in fair value of warrant liability		11,020
Interest income	457,189	987,247
Unrealized gain (loss) on short-term investments	123,044	(1,701,428)
Interest expense	(776,838)	(182,509)
Other expense, net	(104,822)	(482,689)
Total non-operating loss	(301,427)	(1,368,359)
Net loss before income taxes from continuing operations	(42,333,599)	(41,591,004)
Income tax benefit	571,120	215,937
Net loss from continuing operations	(41,762,479)	(41,375,067)
Net loss from discontinued operations before income taxes	(5,005,518)	(5,560,130)
Income tax (expense) benefit from discontinued operations	(65,189)	3,073,000
Net loss from discontinued operations, net of tax benefit	(5,070,707)	(2,487,130)
Net loss	(46,833,186)	(43,862,197)
Net loss - non-controlling interest	(1,616,018)	(427,491)
Net loss attributable to Scorpius Holdings, Inc.	$ (45,217,168)	$ (43,434,706)
Net loss per share, basic - continuing operations (in dollars per share)	$ (1.54)	$ (1.60)
Net loss per share, diluted - continuing operations (in dollars per share)	(1.54)	(1.60)
Net loss per share, basic - discontinued operations (in dollars per share)	(0.19)	(0.10)
Net loss per share, diluted - discontinued operations (in dollars per share)	(0.19)	(0.10)
Net loss per share common share attributable to Scorpius Holdings, Inc., basic	(1.74)	(1.70)
Net loss per share common share attributable to Scorpius Holdings, Inc., diluted	$ (1.74)	$ (1.70)
Weighted-average common shares outstanding, basic (in shares)	26,046,594	25,606,326
Weighted-average common shares outstanding, diluted (in shares)	26,046,594	25,606,326
Comprehensive loss from continuing operations:
Net loss	$ (46,833,186)	$ (43,862,197)
Unrealized (loss) gain on foreign currency translation	(3,047)	119,865
Total comprehensive loss	(46,836,233)	(43,742,332)
Comprehensive loss attributable to non-controlling interest	(1,616,018)	(427,491)
Comprehensive loss - Scorpius Holdings, Inc.	$ (45,220,215)	$ (43,314,841)

NHWK Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 184,925	$ 3,191,714
Short-term investments	2,206,555	35,837,309
Accounts receivable	375,192	81,456
Grant receivable		1,524,522
Estimated fair value of contingent consideration receivable, related party	268,000
Prepaid expenses and other current assets	817,029	1,491,123
Inventory	909,158
Current assets of discontinued operations		7,928,136
Total Current Assets	4,760,859	50,054,260
Property and Equipment, net	17,587,337	20,438,521
Operating lease right-of-use asset	6,041,439	5,866,261
Finance lease right-of-use asset	20,473,742	15,329,075
Other assets	203,135	260,011
Deposits	251,115	270,461
Contingent earn-out receivable, related party	1,720,000
Non-current assets of discontinued operations		12,178,323
Total Assets	51,037,627	104,396,912
Current Liabilities
Accounts payable	4,109,947	4,213,732
Deferred revenue, current portion	2,359,441	1,585,808
Operating lease liability, current portion	524,208	397,855
Finance lease liability, current portion	904,681	301,048
Accrued expenses and other liabilities	2,201,861	1,916,601
Current liabilities of discontinued operations		9,622,279
Total Current Liabilities	10,100,138	18,037,323
Long Term Liabilities
Deferred revenue, net of current portion	30,000	32,500
Operating lease liability, net of current portion	3,597,014	3,079,887
Financing lease liability, net of current portion	9,016,140	5,520,034
Non-current liabilities of discontinued operations		5,290,500
Total Liabilities	22,743,292	31,960,244
Commitments and Contingencies (Note 11 and 15)
Stockholders' Equity
Common stock, $0.0002 par value; 250,000,000 shares authorized, 26,219,461 and 25,661,488 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	5,244	5,126
Additional paid-in capital	285,713,238	283,019,456
Accumulated deficit	(254,370,827)	(209,153,659)
Accumulated other comprehensive income	48,877	51,924
Total Stockholders' Equity - Scorpius Holdings, Inc.	31,396,532	73,922,847
Non-Controlling Interest	(3,102,197)	(1,486,179)
Total Stockholders' Equity	28,294,335	72,436,668
Total Liabilities and Stockholders' Equity	$ 51,037,627	$ 104,396,912

About NightHawk Biosciences, Inc.

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.

CEO	Mr. Jeffrey Alan Wolf J.D.
WEBSITE	nighthawkbio.com
INDUSTRY	Biotechnology
EMPLOYEES	77

NightHawk Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for NightHawk Biosciences, Inc.? What does NHWK stand for in stocks?

NHWK is the stock ticker symbol of NightHawk Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NightHawk Biosciences, Inc. (NHWK)?

As of Tue Apr 30 2024, market cap of NightHawk Biosciences, Inc. is 5.77 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NHWK stock?

You can check NHWK's fair value in chart for subscribers.

What is the fair value of NHWK stock?

You can check NHWK's fair value in chart for subscribers. The fair value of NightHawk Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NightHawk Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NHWK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NightHawk Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether NHWK is over valued or under valued. Whether NightHawk Biosciences, Inc. is cheap or expensive depends on the assumptions which impact NightHawk Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NHWK.

What is NightHawk Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, NHWK's PE ratio (Price to Earnings) is -0.13 and Price to Sales (PS) ratio is 0.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NHWK PE ratio will change depending on the future growth rate expectations of investors.